145 related articles for article (PubMed ID: 32571711)
21. Association Between Renal Dysfunction and Major Adverse Cardiac Events After Liver Transplantation: Evidence from an International Randomized Trial of Everolimus-Based Immunosuppression.
Saliba F; Fischer L; de Simone P; Bernhardt P; Bader G; Fung J
Ann Transplant; 2018 Oct; 23():751-757. PubMed ID: 30361470
[TBL] [Abstract][Full Text] [Related]
22. Preventive effect of early introduction of everolimus and reduced-exposure tacrolimus on renal interstitial fibrosis in de novo living-donor renal transplant recipients.
Ishida H; Ogura G; Uehara S; Takiguchi S; Nakagawa Y; Hamano N; Koizumi M; Wada T; Fukagawa M; Nakamura M
Clin Exp Nephrol; 2020 Mar; 24(3):268-276. PubMed ID: 31792639
[TBL] [Abstract][Full Text] [Related]
23. Antibody Drug Treatment for Steroid-Resistant Rejection After Pediatric Living Donor Liver Transplantation: A Single-Center Experience.
Hirata Y; Sanada Y; Urahashi T; Ihara Y; Yamada N; Okada N; Katano T; Otomo S; Ushijima K; Mizuta K
Transplant Proc; 2018; 50(1):60-65. PubMed ID: 29407332
[TBL] [Abstract][Full Text] [Related]
24. Everolimus in liver transplantation.
Trotter JF; Lizardo-Sanchez L
Curr Opin Organ Transplant; 2014 Dec; 19(6):578-82. PubMed ID: 25254569
[TBL] [Abstract][Full Text] [Related]
25. Early Switch From Tacrolimus to Everolimus After Liver Transplantation: Outcomes at 2 Years.
Saliba F; Duvoux C; Dharancy S; Dumortier J; Calmus Y; Gugenheim J; Kamar N; Salamé E; Neau-Cransac M; Vanlemmens C; Durand F; Pageaux G; Leroy V; Hardwigsen J; Gharbi H; Masson C; Tindel M; Conti F
Liver Transpl; 2019 Dec; 25(12):1822-1832. PubMed ID: 31631501
[TBL] [Abstract][Full Text] [Related]
26. Everolimus-based Immunosuppression Possibly Suppresses Mean Fluorescence Intensity Values of De Novo Donor-specific Antibodies After Primary Kidney Transplantation.
Narumi S; Watarai Y; Goto N; Hiramitsu T; Tsujita M; Okada M; Futamura K; Tomosugi T; Nishihira M; Sakamoto S; Kobayashi T
Transplant Proc; 2019 Jun; 51(5):1378-1381. PubMed ID: 31056252
[TBL] [Abstract][Full Text] [Related]
27. Ab initio Everolimus-based Versus Standard Calcineurin Inhibitor Immunosuppression Regimen in Liver Transplant Recipients.
Manzia TM; Angelico R; Toti L; Grimaldi C; Sforza D; Vella I; Tariciotti L; Lenci I; Breshanaj G; Baiocchi L; Tisone G
Transplant Proc; 2018; 50(1):175-183. PubMed ID: 29407305
[TBL] [Abstract][Full Text] [Related]
28. Very Early Introduction of Everolimus in De Novo Liver Transplantation: Results of a Multicenter, Prospective, Randomized Trial.
Cillo U; Saracino L; Vitale A; Bertacco A; Salizzoni M; Lupo F; Colledan M; Corno V; Rossi G; Reggiani P; Baccarani U; Bresàdola V; De Carlis L; Mangoni I; Ramirez Morales R; Agnes S; Nure E
Liver Transpl; 2019 Feb; 25(2):242-251. PubMed ID: 30592371
[TBL] [Abstract][Full Text] [Related]
29. Early Everolimus-Facilitated Reduced Tacrolimus in Liver Transplantation: Results From the Randomized HEPHAISTOS Trial.
Nashan B; Schemmer P; Braun F; Schlitt HJ; Pascher A; Klein CG; Neumann UP; Kroeger I; Wimmer P;
Liver Transpl; 2022 Jun; 28(6):998-1010. PubMed ID: 34525259
[TBL] [Abstract][Full Text] [Related]
30. An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients.
Sommerer C; Suwelack B; Dragun D; Schenker P; Hauser IA; Witzke O; Hugo C; Kamar N; Merville P; Junge M; Thaiss F; Nashan B;
Kidney Int; 2019 Jul; 96(1):231-244. PubMed ID: 31027892
[TBL] [Abstract][Full Text] [Related]
31. Clinical experience of tacrolimus with everolimus in heart transplantation.
Wang SS; Chou NK; Chi NH; Huang SC; Wu IH; Wang CH; Yu HY; Chen YS; Tsao CI; Ko WJ; Shun CT
Transplant Proc; 2012 May; 44(4):907-9. PubMed ID: 22564581
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics and Long-Term Safety and Tolerability of Everolimus in Renal Transplant Recipients Converted From Cyclosporine.
Felipe CR; Oliveira NI; Hannun PG; de Paula MI; Tedesco-Silva H; Medina-Pestana JO
Ther Drug Monit; 2016 Feb; 38(1):64-72. PubMed ID: 26274696
[TBL] [Abstract][Full Text] [Related]
33. Mechanistic analyses in kidney transplant recipients prospectively randomized to two steroid free regimen-Low dose Tacrolimus with Everolimus versus standard dose Tacrolimus with Mycophenolate Mofetil.
Traitanon O; Mathew JM; Shetty A; Bontha SV; Maluf DG; El Kassis Y; Park SH; Han J; Ansari MJ; Leventhal JR; Mas V; Gallon L
PLoS One; 2019; 14(5):e0216300. PubMed ID: 31136582
[TBL] [Abstract][Full Text] [Related]
34. Three-year Outcomes in De Novo Liver Transplant Patients Receiving Everolimus With Reduced Tacrolimus: Follow-Up Results From a Randomized, Multicenter Study.
Fischer L; Saliba F; Kaiser GM; De Carlis L; Metselaar HJ; De Simone P; Duvoux C; Nevens F; Fung JJ; Dong G; Rauer B; Junge G;
Transplantation; 2015 Jul; 99(7):1455-62. PubMed ID: 26151607
[TBL] [Abstract][Full Text] [Related]
35. Cumulative experience with pediatric living related liver transplantation.
Colombani PM; Lau H; Prabhakaran K; Maley W; Wise B; Schwarz K; Klein A
J Pediatr Surg; 2000 Jan; 35(1):9-12. PubMed ID: 10646765
[TBL] [Abstract][Full Text] [Related]
36. Daclizumab induction therapy associated with tacrolimus-MMF has better outcome compared with tacrolimus-MMF alone in pediatric living donor liver transplantation.
Schuller S; Wiederkehr JC; Coelho-Lemos IM; Avilla SG; Schultz C
Transplant Proc; 2005 Mar; 37(2):1151-2. PubMed ID: 15848653
[TBL] [Abstract][Full Text] [Related]
37. Plasma Concentration of Antifungal Agent Micafungin for Pediatric Living Donor Liver Transplantation.
Ueno T; Takase K; Deguchi K; Nomura M; Watanabe M; Kamiyama M; Tazuke Y; Kimura T; Okuyama H
Transplant Proc; 2024 Apr; 56(3):602-604. PubMed ID: 38326203
[TBL] [Abstract][Full Text] [Related]
38. Evaluating the efficacy, safety and evolution of renal function with early initiation of everolimus-facilitated tacrolimus reduction in de novo liver transplant recipients: Study protocol for a randomized controlled trial.
Nashan B; Schemmer P; Braun F; Dworak M; Wimmer P; Schlitt H
Trials; 2015 Mar; 16():118. PubMed ID: 25873064
[TBL] [Abstract][Full Text] [Related]
39. Everolimus vs Mycophenolate Mofetil in Combination With Tacrolimus: A Propensity Score-matched Analysis in Liver Transplantation.
De Simone P; Carrai P; Coletti L; Ghinolfi D; Petruccelli S; Precisi A; Campani D; Marchetti P; Filipponi F
Transplant Proc; 2018 Dec; 50(10):3615-3620. PubMed ID: 30577246
[TBL] [Abstract][Full Text] [Related]
40. Conversion of twice-daily to once-daily tacrolimus is safe in stable adult living donor liver transplant recipients.
Kim SH; Lee SD; Kim YK; Park SJ
Hepatobiliary Pancreat Dis Int; 2015 Aug; 14(4):374-9. PubMed ID: 26256081
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
